[
 {
  "trial": "T030",
  "source": "fulltext",
  "arms": {
   "Group S (esketamine)": {
    "randomized": "105",
    "analysed": "102"
   },
   "Group L (saline)": {
    "randomized": "105",
    "analysed": "100"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Pre-partum day 1",
    "values": {
     "Group S (esketamine)": {
      "events": "26",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "31",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Post-partum week 1",
    "values": {
     "Group S (esketamine)": {
      "events": "4",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "2",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 14,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Post-partum week 2",
    "values": {
     "Group S (esketamine)": {
      "events": "2",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "1",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 28,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Post-partum week 4",
    "values": {
     "Group S (esketamine)": {
      "events": "2",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "1",
      "n": "100"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 3, 5 min after administration",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "50",
      "hallucination": "28",
      "visual": "0"
     },
     "Group L (saline)": {
      "dizziness": "4",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "location": "Table 3, 15 min after administration",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "66",
      "hallucination": "2"
     },
     "Group L (saline)": {
      "dizziness": "2",
      "hallucination": "0"
     }
    }
   },
   {
    "window": "emergence",
    "location": "Table 3, When leaving the operating room",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "34",
      "hallucination": "0",
      "visual": "1"
     },
     "Group L (saline)": {
      "dizziness": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "ChiCTR2100054332",
   "date": null
  },
  "note": "Depression entries are Table 2 counts of post-partum depression (PPD), defined as an EPDS score of nine or more, evaluated by psychiatrists; 'Pre-partum day 1' is the bedside questionnaire 1 day before delivery (day -1), and weeks 1, 2 and 4 were telephone interviews. Three (S) and five (L) were lost to follow-up and excluded, so all counts use the analysed 102 and 100 (Table 2 header). Continuous EPDS scores are only in Fig. 3, and NRS at rest and when coughing (4, 8, 24, 48 h) only in Fig. 2, with no printed values (text: cough NRS lower in Group S at 24 h, p = 0.016), so no pain entries. Adverse events (Table 3) at 5 and 15 min after esketamine (given 5 min after delivery, under spinal anaesthesia; both coded intraoperative, as separate entries because the overlap between the two times is unknown) and 'when leaving the operating room' (coded emergence). Table 3 prints diplopia and blurred vision as separate rows: Diplopia S 0 / 2 / 0, L 0 / 0 / 0; Blurred vision S 0 / 1 / 1, L 0 / 0 / 0 (5 min / 15 min / leaving the room). visual is 0 in both arms at 5 min (both rows 0) and S 1, L 0 when leaving the room (no diplopia, so the one blurred-vision case is the only visual case); at 15 min visual is left out for both arms because Group S's 2 diplopia and 1 blurred vision cases may overlap (2 or 3 participants). Nausea, headache and vomiting are also in Table 3 (not coded). Enrollment period not stated.",
  "reason": "The coders differed only on visual in Table 3, which prints diplopia and blurred vision as separate rows. At 5 min both rows are 0 in both arms, so visual is 0; when leaving the operating room Group S had diplopia 0 and blurred vision 1, so exactly one participant had a visual disturbance (coder A's 0 counted diplopia alone); at 15 min Group S had diplopia 2 and blurred vision 1 with the overlap not reported, so visual is left out there for both arms and both rows are given in the note (coder A's 2 was diplopia alone). Coder B's coding is kept; everything the coders agreed on matches the source."
 },
 {
  "trial": "T059",
  "source": "fulltext",
  "arms": {
   "Treatment Arm": {
    "randomized": "30",
    "analysed": "28"
   },
   "Control Arm (saline)": {
    "randomized": "30",
    "analysed": "27"
   }
  },
  "depression": [
   {
    "measure": "Self-rating Depression Scale (SDS), at admission and discharge",
    "day": 28,
    "form": "median_iqr",
    "location": "Table 3, 'Median SDS on Day 28 (Q25, Q75)'",
    "values": {
     "Treatment Arm": {
      "median": "49.8",
      "q1": "43.1",
      "q3": "56.5",
      "n": "28"
     },
     "Control Arm (saline)": {
      "median": "53.1",
      "q1": "47.3",
      "q3": "59.0",
      "n": "27"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-09",
   "end": "2022-12"
  },
  "registration": {
   "number": "ChiCTR2000034069",
   "date": "2020-06-22"
  },
  "note": "60 randomized (30/30); 3 withdrew consent and 2 were excluded for continuous sedation in ICU (arms not stated); analysed 28/27 from the table headers (modified ITT). Methods say SDS was taken on admission and at discharge, but only 'Median SDS on Day 28' is printed (Table 3); admission SDS is not reported. The trial counts days from admission (Day 0); esketamine was given at induction of each of the first 3 surgeries, held at unstated days during the first month after injury, and in the analgesic pump for up to 7 postoperative days, so Day 28 after admission is not a known number of days after the procedure (at most 28 after the first surgery); day is entered as printed (28). The Table 3 'Median (Q25, Q75)' values for SDS, PCL-C and PSQI sit almost symmetrically around the centre (SDS 49.8 (43.1, 56.5) and 53.1 (47.3, 59.0)), which may mean another summary was mislabelled; recorded as printed. Postoperative NPRr and NPRm are only in Fig. 2 (medians with IQR bars, no printed values). Left out as not at 24 or 48 h (Table 2, whole postoperative period, Treatment vs Control): cases with NPRr > 3, 3 (10.7 %) vs 6 (22.2 %); NPRm > 3, 9 (32.1 %) vs 17 (65.4 %); postoperative daily opioid consumption (IV morphine equivalents, mg) 26.0 (16.3, 32.5) vs 35.0 (26.4, 50.9); SAE grade 1-2 on day 28 after admission or at discharge 19 (67.9 %) vs 11 (40.7 %). No psychotomimetic adverse events reported.",
  "reason": "The coders differed only on the day of the SDS entry (28 vs null). Table 3 prints 'Median SDS on Day 28', and the trial counts days from admission (Day 0), with the esketamine surgeries at unstated days in the first month. The codebook makes day a plain number and puts an ambiguous time in the note, so day is 28 as printed (coder A), and the note says it is counted from admission rather than from the procedure. The values, n and everything else match the source."
 },
 {
  "trial": "T067",
  "source": "fulltext",
  "arms": {
   "Control group (placebo)": {
    "randomized": "45",
    "analysed": "42"
   },
   "Low esketamine group (0.2 mg/kg)": {
    "randomized": "45",
    "analysed": "42"
   },
   "High esketamine group (0.5 mg/kg)": {
    "randomized": "45",
    "analysed": "45"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "count",
    "definition": "HADS-D ≥ 8",
    "location": "Table 3, Depression incidence, Preoperative",
    "values": {
     "Control group (placebo)": {
      "events": "15",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "20",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "16",
      "n": "45"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "count",
    "definition": "HADS-D ≥ 8",
    "location": "Table 3, Depression incidence, POD1",
    "values": {
     "Control group (placebo)": {
      "events": "12",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "5",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "1",
      "n": "45"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 3,
    "form": "count",
    "definition": "HADS-D ≥ 8",
    "location": "Table 3, Depression incidence, POD3",
    "values": {
     "Control group (placebo)": {
      "events": "2",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "0",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "1",
      "n": "45"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 2, 'Postoperative Agitation'",
    "values": {
     "Control group (placebo)": {
      "agitation": "3"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "agitation": "5"
     },
     "High esketamine group (0.5 mg/kg)": {
      "agitation": "2"
     }
    }
   },
   {
    "window": "overall",
    "location": "Results 3.6 Side effects (text: no participants reported)",
    "values": {
     "Control group (placebo)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "0"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "0"
     },
     "High esketamine group (0.5 mg/kg)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-06",
   "end": "2022-07"
  },
  "registration": {
   "number": "ChiCTR2100047067",
   "date": null
  },
  "note": "Depression entries are Table 3 counts of depressive symptoms, HADS-D of 8 or more; POD-1 (the day before surgery) is day -1. Continuous HADS-D and the pain VAS at 2, 24, 48 and 72 h are only in Fig. 3 (no printed values), so no pain entries. 135 randomized (45 per arm); six lost (withdrawal of consent or no follow-up): analysed 42/42/45. Postoperative agitation (Table 2) is printed as counts without percentages. Results 3.6 says no participants reported nightmares, dizziness, itching, urinary retention, convulsions or hallucinations, with no window stated; entered as 0 in every arm in a separate entry coded overall (esketamine was given under general anaesthesia, and follow-up ran to POD3).",
  "reason": "The coders differed only on the window of the zeros from Results 3.6 ('no participants reported experiencing nightmares, dizziness ... or hallucinations'). That sentence states no window, and the drug was given under general anaesthesia with follow-up to POD3, so the zeros are coded overall in their own entry (coder A) rather than folded into the postoperative window of Table 2's 'Postoperative Agitation' counts, which keep that window. Everything else matches the source."
 },
 {
  "trial": "T074",
  "source": "fulltext",
  "arms": {
   "Esketamine group (group E)": {
    "randomized": "50",
    "analysed": "50"
   },
   "Control group (group C)": {
    "randomized": "50",
    "analysed": "48"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": -1,
    "form": "count",
    "definition": "EPDS category 'Depression' (Table 4; cut-offs not stated; the separate 'Mild' category not included)",
    "location": "Table 4, Preoperative depression",
    "values": {
     "Esketamine group (group E)": {
      "events": "0",
      "n": "50"
     },
     "Control group (group C)": {
      "events": "3",
      "n": "48"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 2,
    "form": "count",
    "definition": "EPDS category 'Depression' (Table 4; cut-offs not stated; the separate 'Mild' category not included)",
    "location": "Table 4, Postoperative depression (postoperative day 2)",
    "values": {
     "Esketamine group (group E)": {
      "events": "0",
      "n": "50"
     },
     "Control group (group C)": {
      "events": "1",
      "n": "48"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "maximum NRS pain within 24 h",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text, paragraph after Table 1",
    "values": {
     "Esketamine group (group E)": {
      "median": "5",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Control group (group C)": {
      "median": "6",
      "q1": "5",
      "q3": "6",
      "n": null
     }
    }
   },
   {
    "measure": "NRS moving incision pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text after Fig 3, Moving incision pain 12–24 h",
    "values": {
     "Esketamine group (group E)": {
      "median": "4",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Control group (group C)": {
      "median": "5",
      "q1": "4",
      "q3": "5",
      "n": null
     }
    }
   },
   {
    "measure": "NRS rest incision pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text after Fig 3, Rest incision pain 12–24 h",
    "values": {
     "Esketamine group (group E)": {
      "median": "2",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Control group (group C)": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": null
     }
    }
   },
   {
    "measure": "NRS visceral pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text after Fig 3, Visceral pain 12–24 h",
    "values": {
     "Esketamine group (group E)": {
      "median": "4",
      "q1": "2.75",
      "q3": "4.25",
      "n": null
     },
     "Control group (group C)": {
      "median": "5",
      "q1": "4",
      "q3": "5.75",
      "n": null
     }
    }
   },
   {
    "measure": "PCIA presses, rescue analgesic dose, total PCIA consumption",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3, '12–24 h postoperatively PCIA consumption (mL)'",
    "values": {
     "Esketamine group (group E)": {
      "median": "34.00",
      "q1": "30.00",
      "q3": "43.50",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "33.00",
      "q1": "27.00",
      "q3": "44.25",
      "n": "48"
     }
    }
   },
   {
    "measure": "PCIA presses, rescue analgesic dose, total PCIA consumption",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3, '12–24 h postoperatively NOC of PCIA (times)'",
    "values": {
     "Esketamine group (group E)": {
      "median": "4.00",
      "q1": "2.00",
      "q3": "7.25",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "3.00",
      "q1": "2.00",
      "q3": "6.75",
      "n": "48"
     }
    }
   },
   {
    "measure": "pressure pain threshold and tolerance (30 min, 24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text, PPT (kgf) T2",
    "values": {
     "Esketamine group (group E)": {
      "median": "2.03",
      "q1": "1.6",
      "q3": "2.83",
      "n": null
     },
     "Control group (group C)": {
      "median": "2.15",
      "q1": "1.8",
      "q3": "2.8",
      "n": null
     }
    }
   },
   {
    "measure": "pressure pain threshold and tolerance (30 min, 24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text, PTO (kgf) T2",
    "values": {
     "Esketamine group (group E)": {
      "median": "3.88",
      "q1": "2.62",
      "q3": "4.83",
      "n": null
     },
     "Control group (group C)": {
      "median": "3.85",
      "q1": "3.33",
      "q3": "4.92",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 5 (side effects at 24 h postoperatively)",
    "values": {
     "Esketamine group (group E)": {
      "dizziness": "4",
      "nightmare": "5",
      "visual": "1"
     },
     "Control group (group C)": {
      "dizziness": "3",
      "nightmare": "2",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-12-12",
   "end": "2025-04-18"
  },
  "registration": {
   "number": "ChiCTR2300078310",
   "date": null
  },
  "note": "Two group C dropouts (PCIA failure 3 h and voluntary withdrawal 8 h after surgery); 98 analysed (50/48). Depression: Table 4 gives EPDS categories No / Mild / Depression without cut-offs; events = the 'Depression' row. Mild: preoperative E 13 (26%), C 8 (16.7%); postoperative day 2 E 2 (4%), C 7 (14.6%). No: preoperative E 37, C 37; postoperative E 48, C 40. The text's lower postpartum depression in group E (P = 0.038) tests the whole distribution. Pain was measured only to 24 h. The NRS interval entries are the maximum in the 12–24 h interval, entered as day 1 (0–6 and 6–12 h left out); they, the maximum NRS within 24 h, and PPT and PTO are printed in the Results text with no n. Group C's visceral 12–24 h upper quartile is printed '5. 75' (recorded 5.75), and its rest 12–24 h IQR '[1, 3]'. The design's PCIA measure has two Table 3 rows at 12–24 h, PCIA consumption (mL) and number of compressions (times), both under the design's name and told apart by location; both are values for the 12–24 h interval, not cumulative to 24 h. Rescue analgesia: one group C patient received 150 mg tramadol. PPT and PTO: T0/T1/T2 are not defined in the text; Methods measure them preoperatively and at 30 min and 24 h postoperatively, so T2 is taken as 24 h (day 1); both are under the design's name, told apart by location. Left out as cumulative over 0–24 h rather than at 24 h, and not a design measure (Table 2, E vs C): cumulative resting pain score 4 (3–5) vs 5(4–6); cumulative moving pain score 11 (10–12) vs 13 (12–14.75); cumulative visceral pain score 9.14 ± 3.02 vs 11.79 ± 2.47. Side effects (Table 5) were assessed at 24 h postoperatively; diplopia coded as visual; not coded: drowsiness 5 vs 2, nausea and vomiting 8 vs 2. Results say there was no unblinding (no guess data).",
  "reason": "The coders differed on pain entries. Measure names follow the design, so the 12–24 h number of PCIA compressions goes under the design's PCIA measure and PTO under the design's pressure pain threshold and tolerance measure (coder A), not under source names (coder B); the values are the same. Table 2's cumulative resting, moving and visceral NRS scores are sums over the 0–24 h intervals, not scores at 24 h, and no design measure names them; they would duplicate the design's NRS measures on another scale, so they are left out (coder B) and given in the note. Everything else matches the source."
 }
]